In this Literary Cafe series, I attempt to reproduce the findings from Wu and colleagues’ paper, “Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes“ (link).
In this first part (with subsequent parts to follow), I demonstrate how we can use the same publicly available data from the Agency of Healthcare Research and Quality (AHRQ) Medical Expenditure Panel Survey (MEPS) to reproduce the sample used by Wu and colleagues in their study (link).
I published this article in my RPubs page (link).